Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
On December 17, 2020, Annovis Bio (NYSE American: ANVS) announced that CEO Maria Maccecchini, Ph.D., will be featured in an interview on The RedChip Money Report. The program reaches 100 million homes across Europe and airs on Sundays at 6 p.m. local time on Bloomberg International. In the interview, Maccecchini discusses Annovis' innovative approach to treating Alzheimer’s disease (AD) and other neurodegenerative diseases, the ongoing clinical trials, and anticipated milestones. Annovis is developing a drug aimed at improving nerve cell function affected by neurotoxic proteins.
- CEO interview on a major platform could enhance company visibility.
- Unique drug approach targeting multiple neurotoxic proteins.
- Ongoing Phase 2a clinical trials for AD and PD patients.
- Statements in the PR include forward-looking statements that may encounter risks and uncertainties, such as potential clinical trial delays.
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.
In the exclusive interview, Dr. Maccecchini discusses the Company’s unique approach to AD and other neurodegenerative diseases, current clinical trials underway, and upcoming milestones.
To view the interview segment, please visit: https://youtu.be/GVakTzykHYg
“The RedChip Money Report" delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.
Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
FAQ
What is Annovis Bio focusing on in its clinical trials?
When will the interview with Annovis Bio's CEO air?
What is the stock symbol for Annovis Bio?
What are the key takeaways from the Annovis Bio interview?
What risks are associated with Annovis Bio's forward-looking statements?
